Mesenchymal stem cell-derived exosomes for treatment of sepsis.

The pathogenesis of sepsis is an imbalance between pro-inflammatory and anti-inflammatory responses. At the onset of sepsis, the lungs are severely affected, and the injury progresses to acute respiratory distress syndrome (ARDS), with a mortality rate of up to 40%. Currently, there is no effective treatment for sepsis. Cellular therapies using mesenchymal stem cells (MSCs) have been initiated in clinical trials for both ARDS and sepsis based on a wealth of pre-clinical data. However, there remains concern that MSCs may pose a tumor risk when administered to patients. Recent pre-clinical studies have demonstrated the beneficial effects of MSC-derived extracellular vesicles (EVs) for the treatment of acute lung injury (ALI) and sepsis. After recovery of initial surgical preparation, pneumonia/sepsis was induced in 14 adult female sheep by the instillation of The infusion of MSCs-EVs was well tolerated without adverse events. PaO We have previously demonstrated the beneficial effects of bone marrow-derived MSCs (10×10

Informations de copyright

Copyright © 2023 Homma, Bazhanov, Hashimoto, Shimizu, Heathman, Hao, Nawgiri, Muthukumarana, Lee, Prough and Enkhbaatar.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.